Editas Advances EDIT-401 with Australian HREC Approval and Extends Cash Runway to 2028

What happened

Editas Medicine reported Q3 2026 results, announcing HREC approval to initiate the Phase 1/2 Strive study of EDIT-401 in hyperlipidemia in Australia, marking a key regulatory milestone. New preclinical data presented at AHA showed ≥90% LDL-C reduction maintained over 10 months, supporting EDIT-401's potential best-in-class profile and de-risking durability concerns. The company also highlighted a second IND/CTA acceptance for its CD70 HD Allo CAR T program with Bristol Myers Squibb, triggering a milestone payment and validating its collaboration revenue stream. Cash runway was extended into the second half of 2028, through and beyond key Strive readouts, reducing near-term dilution risk relative to the prior Q3 2027 guidance. These developments strengthen the investment thesis from the prior master report, which valued Editas primarily on the EDIT-401 program and balance-sheet support, though human proof-of-concept remains the critical next step.

Implication

The Australian HREC approval for EDIT-401 validates the regulatory path and allows first-in-human dosing, moving the program from preclinical to clinical stage. The extended cash runway to 2H 2028, beyond Strive readouts, reduces the likelihood of a dilutive financing before key data, improving the risk/reward profile. The durable ≥90% LDL-C reduction in preclinical models over 10 months, if translated to humans, would place EDIT-401 among the most potent in vivo LDL-lowering approaches, potentially exceeding Verve/Lilly benchmarks. However, preclinical success does not guarantee human efficacy or safety; the Strive study will be the true test, and competitive pressure from Verve/Lilly remains intense. We maintain a cautiously positive stance, with the stock likely to re-rate toward the $3.5–5.0 range if early human data confirm the preclinical profile, but downside to $1.0 or below remains if safety or efficacy disappoints.

Thesis delta

The prior thesis hinged on on-time IND/CTA by mid-2026 and cash runway into Q3 2027. With HREC approval achieved and runway extended to 2H 2028, the thesis has strengthened on both regulatory and financing fronts. The key remaining risk is human proof-of-concept; if Strive data show strong LDL-C lowering with clean safety, the stock could re-rate significantly.